Vaxcyte, Inc. — Director's Dealing 2026

Mar 3, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2026-02-26

Reporting Person: Wassil Jim (CHIEF OPERATING OFFICER)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-26	Common Stock	A	32045	—	Acquired	173893	Direct
2026-02-27	Common Stock	A	5102	$61.74	Acquired	178995	Direct
2026-02-27	Common Stock	F	1900	$61.74	Disposed	177095	Direct
2026-02-28	Common Stock	F	898	$61.98	Disposed	176197	Direct
2026-03-02	Common Stock	F	1009	$61.98	Disposed	175188	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-26	Stock Option (right to buy)	$60	A	53566	Acquired	2036-02-26	Common Stock (53566)	Direct

Footnotes

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The
RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through
each such date.

F2: Represents RSUs issued in lieu of a cash bonus by election of the Reporting Person, such election available to all of Issuer's senior management. The RSUs are fully vested upon the date of grant.

F3: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

F4: 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.